Breath-Actuated Qvar RediHaler Available for Asthma Maintenance Treatment

Teva is discontinuing sales of previously available Qvar with the launch of Qvar Redihaler
Teva is discontinuing sales of previously available Qvar with the launch of Qvar Redihaler

Teva announced the launch of Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol for the maintenance treatment of asthma as a prophylactic therapy in patients aged 4 years and older.

Qvar RediHaler is the first breath-actuated aerosol inhaled corticosteroid indicated for this condition. Unlike metered-dose inhalers (MDIs), the breath-actuated inhaler does not require hand-breath coordination during inhalation. Qvar RediHaler delivers the same active ingredient contained in Qvar Inhalation Aerosol but through novel breath-actuated inhaler technology. 

The Qvar RediHaler will be replacing the Qvar metered-dose inhaler; Teva is discontinuing sales of Qvar with this launch. 

Related Articles

Qvar RediHaler is available as 40mcg and 80mcg strengths in 10.6g canisters containing 120 actuations each. No shaking or priming is needed with Qvar RediHaler and it should not be used with a spacer or volume holding chamber. Shaking the inhaler with the cap open may cause possible actuation of the device.

For more information call (800) 483-8279 or visit Qvar.com.